New Discovery May Reverse Chronic Inflammation, Scientists Find

The thymus shrinks with every passing decade. By the time most adults reach their 70s, the organ has largely been replaced by fat and fibrous tissue, a process so routine that for decades it was treated as biologically unremarkable. What researchers at the University of Southern California now suspect is that this quiet disappearance may be one of the primary reasons the aging body turns against itself.

The key, they found, is not the thymus itself, but a hormone it produces. That hormone has a measurable, causal relationship with one of the most consequential biological processes in human aging, and it has been declining inside every adult body, silently, for years. All of the evidence for this mechanism, it should be noted upfront, comes from animal studies and human blood sample analysis. Whether these findings will translate to human treatments remains an open question, one the researchers themselves are careful to emphasize.

These are findings from mice. But the biological mechanism they expose – connecting thymic decline to chronic inflammation to cancer vulnerability – is precise enough that it may reshape how scientists think about what drives age-related disease, and where to look for ways to reverse chronic inflammation at its source.

The Science of Inflammaging: What Happens When the Immune System Stays on Alert

Researchers from the Keck School of Medicine of USC identified the thymus, a small organ behind the breastbone that plays a central role in immune system development, as a key player in inflammaging. The word “inflammaging” is a portmanteau, but the biology behind it is anything but casual. The chronic, low-grade inflammation that increases with age fuels cancer and other diseases, a state researchers have labeled inflammaging.

The National Institute on Aging describes it as “chronic, sterile, low-grade inflammation,” sterile because it arises without any infection driving it. The immune system doesn’t encounter a pathogen and mount a response; it simply stays partially activated all the time. Over years and decades, that background activation accumulates damage across virtually every organ system.

The disease burden linked to this process is substantial. A range of conditions have been linked to inflammaging, including diabetes, chronic kidney disease, and Alzheimer’s disease. Chronic inflammation has also been recognized as a key contributor to cancer initiation, progression, and treatment response. The American College of Cardiology’s 2025 scientific statement in JACC confirmed that chronic, low-grade inflammation plays a crucial role in the pathogenesis and clinical outcomes of cardiovascular disease.

During aging, organisms develop a characteristic inflammatory state that expresses high levels of pro-inflammatory markers, and this chronic inflammation is considered the major risk factor for age-related diseases. The mechanism involves a deterioration of immune system function known as immunosenescence, in which the body’s defenses weaken at the same time they become persistently over-active. The age-related immune remodeling is associated with increased risk for cancers and chronic infections, while the efficiency of vaccination and immunotherapy declines with aging.

At the cellular level, the process involves specific immune cells becoming dysregulated. Mature myeloid immune cells, a class of white blood cells involved in the front-line immune response, display altered phenotypes in aged individuals, with elevated production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. These cytokines, signaling proteins that coordinate immune activity, are the molecular messengers of inflammation. When their levels stay chronically elevated, they do not protect; they corrode.

Why Age Is the Dominant Cancer Risk Factor

Aging is a major risk factor for cancer, with immunosenescence contributing to increased susceptibility. The pathway from chronic inflammation to tumor development is increasingly well-mapped. Immunosenescence is linked to higher rates of chronic diseases and mortality in the elderly; this decline in immune function impairs the body’s ability to defend against pathogens and allows tumor cells to evade immune surveillance, facilitating tumor development and leading to higher rates of treatment failure and recurrence.

Chronic inflammation can weaken the immune system’s ability to attack tumors and may reduce the effectiveness of immune checkpoint inhibitors, the class of treatments that has transformed oncology over the past decade. If inflammaging is blunting immunotherapy responses in older patients before treatment even begins, addressing that inflammatory state becomes a clinical priority, not just a research question.

The Thymus and Thymulin: Identifying the Biological Mechanism to Reverse Chronic Inflammation

For decades, the thymus was best known for one function: producing T-cells. These are the immune system’s precision strike force, trained to identify and destroy specific threats. But as Fumito Ito, MD, PhD, professor of surgery and immunology at the Keck School of Medicine and lead author of the 2026 study, explained: “The thymus is best known for producing T-cells that allow the immune system to fight infections and cancer, but our findings show it also helps keep age-related inflammation in check.”

Ito described the finding this way: “This is the first evidence of a substance that is naturally produced in the thymus, declines with age, and has the power to reverse age-related inflammation.”

The substance is thymulin. Thymulin is a thymus-derived peptide that declines with age, identified in the USC study as a mediator that suppresses pro-inflammatory cytokine production. At a structural level, thymulin is a nine-amino-acid thymic hormone that is biologically active only when bound to one zinc ion, making it a zinc-dependent nonapeptide. Zinc deficiency, itself more common in older adults, may further impair thymulin function and compound the inflammatory cascade.

The USC team found that thymulin helps regulate the body’s cytokines, keeping inflammation under control, and that as thymulin levels fall with age, cytokines increase. As the thymus atrophies across adult life and produces less thymulin, the brakes on systemic inflammation weaken, and the chronic low-grade fire of inflammaging takes hold.

Thymic Involution: A Decades-Long Decline

The aging thymus undergoes progressive atrophy, a process called thymic involution. Natural aging causes the thymus to progressively atrophy, resulting in structural alterations and functional decline, ultimately producing significantly decreased thymic output of naïve T cells, which reduces the diversity of the T-cell receptor repertoire and disrupts T-cell homeostasis. This atrophy is not sudden; it begins in early adulthood and continues steadily through life. The loss of thymulin production follows the same trajectory, and as thymulin decreases, inflammation increases, allowing diseases like cancer to progress.

The link between thymic involution and inflammaging had been suspected before this research. Studies have demonstrated that the increased release of autoreactive T cells from the involuted thymus contributes to the development of inflammaging, and that this age-related increase in autoreactive T-cell release is clinically significant even in the absence of overt autoimmune disease. What the USC team added was the identification of a specific hormonal mechanism responsible for part of that process, and the demonstration that it could be corrected experimentally, at least in mice.

How the Study Was Conducted: Parabiosis and the Power of Young Blood

Heterochronic parabiosis consists of surgically connecting the circulatory systems of a young and an old animal, a method designed to determine whether factors circulating in younger blood can reverse age-related biological changes. It’s an extreme technique, but a scientifically decisive one: when the researchers connected the circulatory systems of young and old mice, the procedure reduced inflammation in older mice, suggesting that something in young blood may help reverse age-related decline.

To identify what that “something” was, the team combined parabiosis experiments with human blood sample analysis and additional mouse models. The approach allowed them to narrow down the responsible factor from the broad composition of young blood to a specific, measurable molecule: thymulin.

Insights from animal models often fail to translate into successful clinical trials, and this research may help explain why: older mice are biologically distinct from younger mice, yet researchers often rely on younger animals because they are less expensive and easier to study. As Ito noted: “When using young mice, we may be underestimating the impact of age-related chronic inflammation. Studying older animals may be critical for understanding diseases of aging.” This methodological observation carries weight beyond the thymulin finding itself. It challenges standard preclinical research practice in a field where trial failures are common.

Animal Model Results: Survival, Immunity, and Immunotherapy Response

The experimental results in older mice were notable across three distinct outcomes. In older mice with cancer, adding thymulin boosted the immune response against tumors and improved overall survival.

The second finding was equally significant from a treatment perspective. Adding thymulin also made older mice more responsive to anti-PD-1/PD-L1 therapy, a class of checkpoint inhibitor drugs that prevents cancer cells from switching off immune responses against them. PD-1/PD-L1 checkpoint inhibitors are established standard treatments across multiple cancer types, yet their efficacy in older patients has long been inconsistent. If thymulin deficiency is a driver of that inconsistency, restoring it could meaningfully improve outcomes in the population most likely to develop cancer in the first place.

The study published in Nature Communications on July 21, 2026, and funded by the National Institutes of Health, describes these combined findings as uncovering “a thymus-myeloid cell regulatory axis linking aging, inflammation, and cancer immunity.” The study authors suggest thymulin as a potential strategy to improve cancer immunotherapy in older individuals.

Limitations and What Remains to Be Proven

The results are significant, but they are animal results, and the gap between a mouse model and a human clinical outcome is well-documented. Whether the same mechanism operates in humans, and whether boosting thymulin could one day have clinical benefits, remains to be determined. The heterochronic parabiosis model is informative but inherently artificial; surgically joined circulatory systems do not map cleanly onto any therapeutic approach available in human medicine.

The study also cannot yet answer how thymulin would be delivered therapeutically, at what dose, or whether systemic administration would produce the same targeted anti-inflammatory effects seen in the mouse tumor models. The hormone’s zinc-dependence adds a layer of complexity: effective activity requires adequate zinc binding, and any clinical application would need to account for that constraint. These are not reasons to dismiss the research; they are the standard questions that preclinical findings must answer before human trials begin.

What the study does establish clearly is the biological mechanism connecting thymic decline, thymulin loss, cytokine dysregulation, and age-related inflammation. That chain of causation, now documented in peer-reviewed evidence, is a more precise target than the field has previously had.

Read More: Aging Accelerates at Two Specific Life Stages

Key Takeaways

The USC study, published in Nature Communications in July 2026, provides the first documented evidence, in animal models and human blood samples, that a thymus-produced hormone called thymulin declines with age, and that this decline is causally linked to the rise in chronic inflammation, or inflammaging, that drives cancer, cardiovascular disease, Alzheimer’s disease, type 2 diabetes, and chronic kidney disease. These are preclinical findings; no human trials have been announced.

Thymulin works by regulating cytokines, the signaling proteins that control immune activity. As thymulin falls with age, cytokine levels rise and the immune system shifts from acute, targeted defense into a state of persistent, low-grade activation. In older mice, restoring thymulin reduced that inflammation, strengthened the immune response against tumors, improved cancer survival rates, and made checkpoint immunotherapy more effective. The same findings also challenge a foundational assumption in preclinical research: that results from young animal models adequately predict outcomes in older patients. For a field studying diseases of aging, that assumption may be costing more than it saves.

Clinically, thymulin is not yet a treatment option for humans. No trials have been announced, and the translation from mouse models to human medicine requires substantially more work. But the identification of a specific, measurable, and potentially restorable hormonal mechanism underlying chronic age-related inflammation is a concrete advance. For researchers studying how to reverse chronic inflammation at its biological root, it is a more actionable lead than the field has had in some time.

Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.